Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010

PLoS One. 2012;7(8):e44102. doi: 10.1371/journal.pone.0044102. Epub 2012 Aug 30.

Abstract

Background: Published data on the epidemiology of meningococcal disease in Latin America and the Caribbean region is scarce and, when available, it is often published in Spanish and/or in non-peer-reviewed journals, making it difficult for the international scientific community to have access.

Methods: Laboratory data on 4,735 Neisseria meningitidis strains was collected and reported by the National Reference Laboratories in 19 Latin American countries and the Caribbean Epidemiology Centre (CAREC) between 2006 and 2010 as part of the work carried out by the SIREVA II network. Serogroup and MIC to penicillin, rifampin and chloramphenicol were determined.

Results: Isolates were mainly obtained from patients <5 years, but each year around 25% of isolates came from adult patients. Serogroup distribution was highly variable among countries. Serogroup C was the main cause of disease in Brazil; the majority of disease seen in the Southern cone was caused by serogroup B, but serogroup W135 strains have increased in recent years. In the Andean and Mexico, Central America and Caribbean regions, serogroups B and C were equally present, and serogroup Y was frequently isolated. Isolates were generally susceptible to chloramphenicol, penicillin and rifampin, but almost 60% of isolates characterized in Southern cone countries presented intermediate resistance to penicillin. Five rifampin-resistant isolates have been isolated in Uruguay and Brazil.

Conclusions: Serogroup distribution is highly variable among countries, but some geographic structuring can be inferred from these data. Epidemiological and laboratory data are scarce among Andean and Mexico, Central America and Caribbean countries. Evaluation and implementation of corrective measures on disease surveillance and reporting systems and the implementation of molecular diagnostic techniques and molecular characterization on meningococcal isolates are advised.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Anti-Bacterial Agents / pharmacology
  • Caribbean Region / epidemiology
  • Child
  • Child, Preschool
  • Clinical Laboratory Techniques / methods*
  • Humans
  • Infant
  • Infant, Newborn
  • Latin America / epidemiology
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / microbiology*
  • Microbial Sensitivity Tests
  • Neisseria meningitidis / classification*
  • Neisseria meningitidis / drug effects
  • Neisseria meningitidis / isolation & purification
  • Penicillins / pharmacology
  • Population Surveillance / methods*
  • Rifampin / pharmacology
  • Serotyping
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Rifampin

Grants and funding

Funding to the SIREVA II network was provided by the Canadian International Development Agency (CIDA). Since 2010, funding for meningococcal disease surveillance in 2010 is provided by Sanofi-Pasteur through the Pan-American Health and Education Foundation (PAHEF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.